Anand Grover’s letter to the FT: India should continue to champion its thriving pharmaceuticals industry

29 Jan 2015

India should continue to champion its thriving pharmaceuticals industry

India is the world’s largest exporter of generic medicines, for example providing more than 85 per cent of generic treatment for HIV/Aids in the developing world. These cost a fraction of the brand-name drugs produced by multinational pharmaceutical companies. India should continue to champion its thriving pharmaceutical sector, rather than cave to US pressure for unnecessary reforms to Indian intellectual property laws that allow these lifesaving medicines to be produced and  licensed.

Sir, President Barack Obama’s visit to Delhi saw the US and India pledge to resume talks on a bilateral investment treaty. Bilateral co-operation is always welcome. However, the treaty risks serious adverse effects for millions of people in India and around the world who rely on safe, efficacious, quality, affordable Indian-made generic medicines.

There is no strong evidence that India’s IP laws are obstacles to innovation or investment. Resisting US efforts to stamp out Indian competition in the pharmaceutical sector will boost the health of India’s economy and of patients around the world.

Anand Grover

Delhi, India

Former UN Special Rapporteur on the Right to Health

This entry was posted in Generics. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s